Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...
There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial. An established cardiac myosin ...
Elevated baseline LDH levels predict worse clinical outcomes in heart failure with reduced ejection fraction and modestly ...
The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), and the Japanese Heart Failure Society (JHFS) announced today a new ...
Verywell Health on MSN
Types of heart failure and how they affect you
Medically reviewed by Jeffrey S. Lander, MD Key Takeaways Heart failure happens when the heart can't pump enough blood ...
Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...
HFpEF and HFmrEF represent up to 75% of heart failure cases, yet treatment evidence is limited compared to other heart failure types. The IMPLEMENT-EF initiative aims to map patient journeys, address ...
Study links exosomal microRNA to ventricular remodelling in heart failure. Discover how this biomarker could inform future ...
Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person's internal fat tissue, according to the Adipokine Hypothesis, a new way of ...
Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results